Madrid 2,16 EUR -0,04 (-1,73 %)
Madrid 2,16 EUR -0,04 (-1,73 %)

CORPORATE |  10.28.2022


Thumbnail user

The Board of Directors has ratified the appointment of Marieta Jiménez Urgal as an independent director of MAPFRE S.A., replacing José Antonio Colomer Guiu, who recently stepped down, having reached the maximum age established in the bylaws for belonging to the most senior decision-making body of the company. Marieta Jiménez holds a degree in pharmacy from the University of Salamanca. She is the senior VP for Europe at Merck Biopharma and has more than 20 years of experience working in various executive positions in pharmaceutical multinationals. She also joins the Appointments and Remuneration Committee. With this appointment, the percentage of women comprising the Board exceeds the 40% threshold recommended by the Spanish National Securities and Exchange Commission.

Antonio Miguel-Romero de Olano also joins the same Appointments and Remuneration Committee, while Ana Isabel Fernández Alvarez joins the Steering Committee of MAPFRE S.A. as a member.

Antonio Gómez Ciria will become chair of the Risks and Sustainability Committee, replacing José Antonio Colomer, and will also become a member of the Audit and Compliance Committee. Francisco Marco Orenes also joins the Risk and Sustainability Committee.